Literature DB >> 9737689

Alternative splicing in wild-type AF10 and CALM cDNAs and in AF10-CALM and CALM-AF10 fusion cDNAs produced by the t(10;11)(p13-14;q14-q21) suggests a potential role for truncated AF10 polypeptides.

C C Silliman1, L McGavran, Q Wei, L A Miller, S Li, S P Hunger.   

Abstract

The t(10;11)(p13;q14-21) is a non-random translocation that occurs primarily in T cell acute lymphoblastic leukemias (T-ALL), but has also been observed in leukemias and lymphomas of diverse lineages. In U937, a cell line established from a diffuse histiocytic lymphoma, a t(10;11)(p13;q14-21) fuses AF10 to CALM. AF10 is also fused to MLL by a translocation that appears quite similar at the cytogenetic level, the t(10;11)(p12;q23). Fluorescence in situ hybridization studies have demonstrated that AF10 and CALM are also involved in other hematological malignancies containing t(10;11)(p13;q21), but no data are available concerning the molecular details of AF10-CALM fusion in primary leukemias. Using RT-PCR, we amplified multiple different isoforms of AF10-CALM and CALM-AF10 fusion cDNAs from a primary T cell ALL containing a t(10;11)(p13-14;q14-21). These cDNAs arose via alternative splicing of exons from both AF10 and CALM, which we demonstrated can also occur in the native genes. We identified at least two novel AF10 exons that can be included in wild-type and fusion cDNAs. The majority of the AF10 and AF10-CALM cDNA isoforms that we identified are predicted to encode for truncated AF10 polypeptides, raising the possibility that these might have important cellular functions in normal and malignant cells, perhaps by acting as dominant negative inhibitors of full-length AF10 or related proteins.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9737689     DOI: 10.1038/sj.leu.2401109

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  6 in total

1.  Exon-skipping in BCR/ABL is induced by ABL exon 2.

Authors:  B D Lichty; S Kamel-Reid
Journal:  Biochem J       Date:  2000-05-15       Impact factor: 3.857

2.  The target cell of transformation is distinct from the leukemia stem cell in murine CALM/AF10 leukemia models.

Authors:  S Dutta; A Krause; S Vosberg; T Herold; B Ksienzyk; L Quintanilla-Martinez; B Tizazu; M Chopra; A Graf; S Krebs; H Blum; P A Greif; A Vetter; K Metzeler; M Rothenberg-Thurley; M R Schneider; M Dahlhoff; K Spiekermann; U Zimber-Strobl; E Wolf; S K Bohlander
Journal:  Leukemia       Date:  2015-12-21       Impact factor: 11.528

3.  A CALM-derived nuclear export signal is essential for CALM-AF10-mediated leukemogenesis.

Authors:  Amanda E Conway; Paula B Scotland; Catherine P Lavau; Daniel S Wechsler
Journal:  Blood       Date:  2013-03-13       Impact factor: 22.113

4.  A role for BMP-induced homeobox gene MIXL1 in acute myelogenous leukemia and identification of type I BMP receptor as a potential target for therapy.

Authors:  Aaron Raymond; Bin Liu; Hong Liang; Caimiao Wei; Michele Guindani; Yue Lu; Shoudan Liang; Lisa S St John; Jeff Molldrem; Lalitha Nagarajan
Journal:  Oncotarget       Date:  2014-12-30

5.  Molecular studies reveal MLL-MLLT10/AF10 and ARID5B-MLL gene fusions displaced in a case of infantile acute lymphoblastic leukemia with complex karyotype.

Authors:  Mitsuteru Hiwatari; Masafumi Seki; Shogo Akahoshi; Kenichi Yoshida; Satoru Miyano; Yuichi Shiraishi; Hiroko Tanaka; Kenichi Chiba; Seishi Ogawa; Junko Takita
Journal:  Oncol Lett       Date:  2017-06-20       Impact factor: 2.967

6.  The PICALM protein plays a key role in iron homeostasis and cell proliferation.

Authors:  Paula B Scotland; Jessica L Heath; Amanda E Conway; Natasha B Porter; Michael B Armstrong; Jennifer A Walker; Mitchell L Klebig; Catherine P Lavau; Daniel S Wechsler
Journal:  PLoS One       Date:  2012-08-30       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.